Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells
Open Access
- 27 December 2010
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 108 (2) , 745-750
Abstract
Inhibition of the DNA repair enzyme poly(ADP-ribose) polymerase 1 (PARP1) with small molecules has been shown to be an effective treatment for ovarian cancer with BRCA mutations. Here, we report the in vivo administration of siRNA to Parp1 in mouse models of ovarian cancer. A unique member of the lipid-like materials known as lipidoids is shown to deliver siRNA to disseminated murine ovarian carcinoma allograft tumors following intraperitoneal (i.p.) injection. siParp1 inhibits cell growth, primarily by induction of apoptosis, in Brca1-deficient cells both in vitro and in vivo. Additionally, the treatment extends the survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells but not from Brca1 wild-type cells, confirming the proposed mechanism of synthetic lethality. Because there are 17 members of the Parp family, the inherent complementarity of RNA affords a high level of specificity for therapeutically addressing Parp1 in the context of impaired homologous recombination.Keywords
This publication has 33 references indexed in Scilit:
- The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical TargetsMolecular Cell, 2010
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer CellsCancer Cell, 2010
- The biology of ovarian cancer: new opportunities for translationNature Reviews Cancer, 2009
- Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasisProceedings of the National Academy of Sciences, 2009
- A combinatorial library of lipid-like materials for delivery of RNAi therapeuticsNature Biotechnology, 2008
- Sequence- and target-independent angiogenesis suppression by siRNA via TLR3Nature, 2008
- A Mouse Model for the Molecular Characterization of Brca1-Associated Ovarian CarcinomaCancer Research, 2006
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survivalOncogene, 2003